Maximus, Inc.
—- Market cap
- $2.98B
- Debt
- —
- Cash
- −$222.35M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: MMS stock price vs AVY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVY's multiple
Needs AVY P/E.
Implied fair value · at MMS's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Maximus, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AVERY DENNISON CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
MMS vs ACN
INTERNATIONAL BUSINESS MACHINES CORP
MMS vs IBM
CACI INTERNATIONAL INC /DE/
MMS vs CACI
ROLLINS INC
MMS vs ROL
CINTAS CORP
MMS vs CTAS
IRON MOUNTAIN INC
MMS vs IRM
3M CO
MMS vs MMM
EASTMAN CHEMICAL CO
MMS vs EMN
ILLINOIS TOOL WORKS INC
MMS vs ITW
RPM INTERNATIONAL INC/DE/
MMS vs RPM
BRADY CORP
MMS vs BRC
METTLER TOLEDO INTERNATIONAL INC/
MMS vs MTD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MMS can sustain its 2.4% revenue growth while preserving its 19.1% ROIC and solid 8/9 Piotroski score, then MMS looks attractive to buy because it trades at roughly half AVY’s P/E and P/S multiples despite healthier leverage.
MMS trades at a steep discount to AVY across earnings, sales, and cash-flow proxies, despite better top-line growth and lower leverage. The implied P/E-based price of $104.68 versus the current $55.77 highlights an 87.7% valuation gap, though the breadth of the discount suggests the market is embedding a meaningful quality or durability differential.
Supporting Metrics